| Identification | More | [Name]
Methadone hydrochloride | [CAS]
1095-90-5 | [Synonyms]
1,1-diphenyl-1-(beta-dimethylaminopropyl)butanone-2hydrochloride
4,4-diphenyl-6-dimethylamino-heptanone-3hydrochloride
6-(dimethylamino)-4,4-diphenyl-3-heptanonhydrochloride
adolan
althosehydrochloride
METHADONE HYDROCHLORIDE OPIOID RECEPTOR AGONI
Methadone Hydrochloride {D.D.}
(+-)-METHADONE HYDROCHLORIDE--DEA*SCHEDU LE II ITEM
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, hydrochloride
(±)-methadone hydrochloride solution
METHADONEHYDROCHLORIDE,USP
Methadone ELISA
1,1-Diphenyl-1-(2-dimethylaminopropyl)-2-butanone hydrochloride
6-Dimethylamino-4,4-diphenyl-3-heptanone hydrochloride
Methadone hydrochloride
rac Methadone Hydrochloride
(±)-Methadone solution hydrochloride | [EINECS(EC#)]
214-140-7 | [Molecular Formula]
CH3ClO | [MDL Number]
MFCD00058014 | [Molecular Weight]
66.49 | [MOL File]
1095-90-5.mol |
| Chemical Properties | Back Directory | [Definition]
A synthetic narcotic. | [Appearance]
White Solid | [Melting point ]
232-2340C | [density ]
1.0103 (rough estimate) | [refractive index ]
1.5790 (estimate) | [Fp ]
11 °C | [storage temp. ]
2-8°C | [solubility ]
Soluble in water, freely soluble in ethanol (96 per cent) | [form ]
powder | [color ]
white to off-white | [Stability:]
Stable. Incompatible with strong oxidizing agents. | [Water Solubility ]
120 mg/mL | [Usage]
Controlled substance (opiate). Used in treatment of opioid dependence | [CAS DataBase Reference]
1095-90-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T,F | [Risk Statements ]
R25:Toxic if swallowed.
R39/23/24/25:Toxic: danger of very serious irreversible effects through inhalation, in contact with skin and if swallowed .
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed .
R11:Highly Flammable. | [Safety Statements ]
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36/37:Wear suitable protective clothing and gloves . | [RIDADR ]
UN 2811 | [WGK Germany ]
3 | [RTECS ]
MJ6300000 | [HS Code ]
2922310000 | [Toxicity]
LD50 orally in rats: 95 mg/kg (Finnegan) |
| Hazard Information | Back Directory | [Hazard]
Toxic. Addictive narcotic. Use restricted. | [Description]
(±)-Methadone (hydrochloride) (Item No. ISO00145) is an analytical reference material categorized as an opioid.1 (±)-Methadone has analgesic activity.2 Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications. | [Chemical Properties]
White Solid | [Originator]
Dolophine ,Lilly,US,1947 | [Uses]
Controlled substance (opiate). Methadone hydrochloride is used in treatment of opioid dependence.
| [Manufacturing Process]
Diphenylacetonitrile is condensed with 2-chloro-1-dimethylaminopropane to give 4-(dimethylamino)-2,2-diphenyl valeronitrile. It is then reacted with ethyl magnesium bromide and then hydrolyzed using HCl to give methadone hydrochloride. | [Brand name]
Dolophine Hydrochloride (Roxane); Dolophine Hydrochloride (Xanodyne);
Methadose (Mallinckrodt); Westadone (Sandoz). | [Therapeutic Function]
Narcotic analgesic | [Clinical Use]
Treatment of opioid drug addiction
Analgesic for moderate to severe pain | [Drug interactions]
Metabolised in the liver to the Potentially hazardous interactions with other drugs
Analgesics: possible opioid withdrawal with
buprenorphine and pentazocine.
Antibacterials: metabolism increased by rifampicin;
increased risk of ventricular arrhythmias with
delamanid and telithromycin.
Antidepressants: concentration possibly increased
by fluoxetine, fluvoxamine, paroxetine and sertraline;
possible CNS excitation or depression with MAOIs
and moclobemide - avoid; possibly increased
sedative effects with tricyclics; concentration possibly
reduced by St John's wort.
Antiepileptics: concentration reduced by
carbamazepine, phenobarbital and phenytoin.
Antifungals: concentration increased by fluconazole,
ketoconazole, voriconazole and possibly itraconazole
- may need to reduce methadone dose with
voriconazole, avoid with ketoconazole.
Antihistamines: increased sedative effects with
sedating antihistamines.
Antimalarials: increased risk of ventricular
arrhythmias with piperaquine with artenimol -
avoid.
Antipsychotics: enhanced hypotensive and sedative
effects; increased risk of ventricular arrhythmias with
antipsychotics that prolong the QT interval - avoid
with amisulpride.
Antivirals: methadone possibly increases
concentration of zidovudine; concentration
reduced by efavirenz, fosamprenavir and ritonavir;
concentration possibly reduced by abacavir,
nevirapine and rilpivirine; concentration possibly
affected by boceprevir; concentration of didanosine
possibly reduced; increased risk of ventricular
arrhythmias with saquinavir and telaprevir - avoid
with saquinavir and use with caution with telaprevir.
Atomoxetine: increased risk of ventricular
arrhythmias.
Cytotoxics: possible increased risk of ventricular
arrhythmias with bosutinib, ceritinib, panobinostat
and vandetanib.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate
- avoid | [Metabolism]
Metabolised in the liver to the major metabolite
2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine
and the minor metabolite 2-ethyl-3,3-diphenyl-5-
methylpyrrolidine, both of them inactive. Two other
metabolites have also been identified.
These metabolites are excreted in the faeces and urine
with unchanged methadone | [Purification Methods]
The salt crystallises from EtOH, or EtOH/Et2O. |
|